SCHEMBL20697263

SCHEMBL20697263

CCOC(=O)c1cnn2c(N(CCCN3CCOCC3)C(=O)OC(C)(C)C)cc(Cl)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.43
ATM Q13315 1/20 0.39
RAD52 P43351 2/20 0.38
UHRF1 Q96T88 1/20 0.38
KDM4E B2RXH2 4/20 0.38
HSD17B10 Q99714 3/20 0.38
MAPK1 P28482 1/20 0.38
RXFP1 Q9HBX9 2/20 0.38
ADORA3 P0DMS8 1/20 0.37
ADORA2A P29274 1/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
GAA P10253 1/20 0.37
CASP1 P29466 1/20 0.37
KLK7 P49862 1/20 0.37
LMNA P02545 1/20 0.37
ABCB1 P08183 1/20 0.37
ABCC1 P33527 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20689052 0.95 POLB (0.41) POLBATMKDM4EHSD17B10RXFP1
SCHEMBL17190170 0.86 TSHR (0.35) KDM4EHSD17B10MAPK1MEN1KMT2A
SCHEMBL20687893 0.86 HPGD (0.38) POLBKDM4EMEN1KMT2AALDH1A1
SCHEMBL20697264 0.82 TYK2 (0.55)
SCHEMBL17190167 0.81 SIGMAR1 (0.35) POLBMEN1KMT2AALDH1A1GAA
SCHEMBL20687897 0.81 TYK2 (0.46) POLBKDM4EMEN1KMT2AALDH1A1
SCHEMBL20689059 0.79 TYK2 (0.47) KDM4EALDH1A1HPGDLMNAABCB1
SCHEMBL20688924 0.79 KDM4E (0.44) POLBKDM4EHSD17B10ADORA3ADORA2A
SCHEMBL20627811 0.78 ACHE (0.35) KDM4ELMNASMN1; SMN2
SCHEMBL20697268 0.78 MEN1 (0.54) POLBATMRAD52UHRF1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-02-23 US disclosed
US-11046698-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2021-06-29 US disclosed
US-10577373-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-03-03 US disclosed
US-10570145-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-25 US disclosed
US-10562906-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-18 US disclosed
US-10562907-B2 TYK2 inhibitors and uses thereof Nimbus Lakshimi, Inc. (US) 2020-02-18 US disclosed
US-20190256519-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-22 US disclosed
US-20190248797-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-15 US disclosed
US-20190241576-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 US disclosed
US-20190241577-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 US disclosed
US-20190241575-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-08-08 US disclosed
US-20190031664-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190248797-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 POLB 1657/4885ATM 759/4885RAD52 1478/4885
US-11046698-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 POLB 1657/4885ATM 759/4885RAD52 1478/4885
US-20190256519-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 POLB 1657/4885ATM 759/4885RAD52 1478/4885
US-20190031664-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 POLB 1657/4885ATM 759/4885RAD52 1478/4885
US-20190241577-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 POLB 1657/4885ATM 759/4885RAD52 1478/4885
US-10562906-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 POLB 1657/4885ATM 759/4885RAD52 1478/4885
US-20190241576-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 POLB 1657/4885ATM 759/4885RAD52 1478/4885
US-20190241575-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 POLB 1657/4885ATM 759/4885RAD52 1478/4885
US-20230056447-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 POLB 1657/4885ATM 759/4885RAD52 1478/4885
US-10570145-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 POLB 1657/4885ATM 759/4885RAD52 1478/4885
US-10577373-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 POLB 1657/4885ATM 759/4885RAD52 1478/4885
US-10562907-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 POLB 1657/4885ATM 759/4885RAD52 1478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.